Docoh
Loading...

AVXL Anavex Life Sciences

GRANT
Utility
Anavex2-73 for the treatment of alzheimer's disease
31 Aug 21
Composition and method for treatment of Alzheimer's disease that includes ANAVEX2-73.
Marco Cecchi
Filed: 27 Sep 19
APP
Utility
Neurodevelopmental Disorder Therapy
29 Jul 21
This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders.
Christopher U. Missling
Filed: 8 Jan 21
GRANT
Utility
Treatment of cardiac dysfunction
27 Jul 21
A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or pharmaceutically acceptable salt thereof or combination thereof.
Christopher U. Missling
Filed: 22 Oct 18
APP
Utility
Crystal Forms of TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE Hydrochloride, Processes of Making Such Forms, and Their Pharmaceutical Compositions
22 Jul 21
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized.
Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York
Filed: 5 Apr 21
APP
Utility
Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
1 Jul 21
A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(pheny)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
Christopher U. Missling
Filed: 12 Feb 21
APP
Utility
SIGMA-1 Receptor Agonist Systolic Blood Pressure Therapy
24 Jun 21
A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
Christopher U. MISSLING
Filed: 28 Nov 18
APP
Utility
A2-73 Crystalline Polymorph Compositions of Matter and Methods of Use Thereof
22 Apr 21
The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms.
Christopher U. MISSLING
Filed: 12 Apr 19
GRANT
Utility
Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
6 Apr 21
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized.
Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York
Filed: 29 Jul 19
APP
Utility
A2-73 As a Therapeutic for Insomnia, Anxiety, and Agitation
25 Mar 21
A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation.
Christopher U. Missling
Filed: 27 Jul 17
GRANT
Utility
Analgesic therapeutic and method, 1-(3-4(((1 R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
2 Mar 21
A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
Christopher U. Missling
Filed: 4 Feb 19
APP
Utility
A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy
18 Feb 21
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED.
Christopher U. Missling, Cameron Durrant
Filed: 26 Oct 20
GRANT
Utility
Neurodevelopmental disorder therapy
12 Jan 21
This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders.
Christopher U. Missling
Filed: 17 Dec 19
GRANT
Utility
A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
26 Oct 20
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED.
Christopher U. Missling, Cameron Durrant
Filed: 13 Oct 19
APP
Utility
Neurodevelopmental Disorder Therapy
5 Aug 20
This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders.
Christopher U. MISSLING
Filed: 16 Dec 19
APP
Utility
A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy
5 Feb 20
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED.
Christopher U. Missling, Cameron Durrant
Filed: 13 Oct 19
APP
Utility
Anavex2-73 for the Treatment of Alzheimer's Disease
22 Jan 20
Composition and method for treatment of Alzheimer's disease that includes ANAVEX2-73.
Marco Cecchi
Filed: 26 Sep 19
GRANT
Utility
Neurodevelopmental disorder therapy
16 Dec 19
This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders.
Christopher U. Missling
Filed: 23 Jan 17
APP
Utility
Crystal Forms of TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE Hydrochloride, Processes of Making Such Forms, and Their Pharmaceutical Compositions
20 Nov 19
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized.
Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York
Filed: 28 Jul 19
GRANT
Utility
A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
14 Oct 19
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED.
Missling U. Christopher, Durrant Cameron
Filed: 18 Oct 15
GRANT
Utility
Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
30 Sep 19
Composition and method for treatment of Alzheimer's disease that includes ANAVEX2-73.
Marco Cecchi
Filed: 13 Jun 17
  • 1
Patents are sorted by USPTO publication date, most recent first